| 证券代码 | ONSIZ.O |
| 证券名称 | Oncobiologics Inc Series B Wt |
| 证券类型 | 美国权证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2016-06-13 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | - |
| 公司名称 | Outlook Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 7 Clarke Drive Cranbury, New Jersey, USA |
| 成立日期 | 2010-01-05 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.outlooktherapeutics.com. |
| 电话 | +1 (609) 619-3990 |
| 传真 | - |
| 公司简介 | Outlook Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. The company currently focuses on technically challenging and commercially attractive monoclonal antibodies, or mAbs, in the disease areas of immunology and oncology. The strategy is to develop these biosimilars in a cost-effective manner on an accelerated timeline, which is fundamental to the success and is believed positions company to be a leading biosimilar company. Comapny has leveraged its team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which it refer to as BioSymphony Platform. The leadership team has been instrumental in obtaining global regulatory approval for multiple complex biologics at leading multinational biopharmaceutical companies. |